This was where we travelled to last week with Ali driving us.
Patient & Carer Day – Friday 13 October 2017
Mesothelioma UK hosted the 12th annual Patient and Carer Day for people with mesothelioma and their families, friends and carers. It was a day of learning, sharing experiences and meeting others in similar situations.
The Lensbury Hotel, Broom Road, Teddington, TW11 9NU what a wonderful hotel. We had a lovely room that overlooked the front the one behind the tree on the left of this photo.
We arrived and booked in and then met friends as they arrived
We went to our room where I worked for a while before sleeping.
Up very early we signed in and the conference began .
With this all over we had to say our goodbyes and travelled home. As it was Friday we thought the roads would be bad but it really wasn’t and we soon got home.
The Conference has been on all week in Japan. I was invited but I have worked so hard recently with so many conferences and also bringing together the guest list for the MNF Launch Dec 7th and then the Scan Day which I was convinced was going to be bad as I get pains in the chest and the arms and hands are so weird and twisted still But it was a good result again so much so I can have the scan every 3 months now.
So the message from Japan
Dear Doctors, Dear Colleagues, Dear Friends,
The 18th World Conference on Lung Cancer of the International Association for the Study of Lung Cancer (IASLC) will take place from October 15 – 18, 2017, in Yokohama, Japan. The science of lung cancer is advancing rapidly, so the IASLC recently decided to hold the World Conferences annually. The IASLC WCLC in Yokohama will be the second of the annual Conferences, following the IASLC World Conference in Vienna, Austria, in 2016.
On behalf of IASLC as well as the members of the Organizing and Program Committees, we would like to cordially invite you to attend the World Conference on Lung Cancer 2017 in Yokohama.
The Conference motto “Synergy to Conquer Lung Cancer” captures the collaborative spirit of the Conference which will be both a scientific and educational event.
Medical doctors, scientists, nurses, health professionals, government officials, partners from the industry, health advocacy groups and patients will come together in order to obtain and exchange information on advances in the management of lung cancer and other thoracic malignancies, while considering both global and regional aspects.
We ask you to submit your latest research results for presentation. You are also welcome to suggest any topic, activity or scientific program you would like to see covered during the World Conference. Your active contribution will be crucial to the success of the World Conference and its impact on our global mission to prevent, diagnose and treat lung cancer and other thoracic malignancies. Together, we will become a stronger voice and global force with the ultimate goal of succeeding in decreasing the world-wide burden of lung cancer.
We hope that, despite an intense Conference program, you also will be able to get some glimpses of Yokohama, Japan. Yokohama is the second largest city in Japan and is a cosmopolitan and modern city, which has played host to many international organizations. Yokohama is also a city rich in history, architecture and culture.
We look forward to personally welcoming you to Yokohama for the World Conference on Lung Cancer 2017, from all parts of the world.
Dr. Hisao Asamura, MD and Dr. Keunchil Park, MD, PhD
IASLC WCLC 2017 Conference Co-Presidents
Dr Peter Szlosarek, chief and principal investigator of several clinical studies here at the Barts Cancer Centre, will this Wednesday 18th October present exciting new data at the IASLC’s (International Association for the Study of Lung Cancer) 18th World Conference on Lung Cancer, Yokohama, Japan.
Highlighting plans for future clinical studies, his talk, “Pegylated Arginine Deiminase Potentiates PD-1/PDL-1 Immune Checkpoint Blockade in Malignant Mesothelioma” will focus on the synergism between the arginine-lowering agent (AID-PEG20, Polaris Pharma) and PD1/PD-L1 axis immune checkpoint blockade in ASS1 negative tumours.
These new developments follow on from the success of the first-ever randomised trial of ADI-PEG20 in mesothelioma (ADAM) that reported an improvement in progression free survival
The Mars Trial is doing well Eric Lim is so pleased with the uptake well today I have him 3 more patients contacting.
Mars Trial is doing so well Eric Lim and David Waller are so pleased with mesowarriors –showing the figures in Japan 88 randomisations to date in #MARS2 for #mesothelioma Recruitment to MARS 2 smashing it. Wonderful to see. #mesothelioma #wclc2017 @_johnedwards
And the last message for the Doctors to take home I always say Give us the trails and I will give them the Mesowarriors we take the chance as we are all so positive and even if we get one more day or one more month that is all we ask. Just to stay a bit longer with our loved ones.Thank you IASLC for this message it is the right one
That is so true I love it xx